Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (161-170 of 346) with videos related to

Pageof 35
Sort By:
American Journal of Hematology|February 13, 2021
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemiaSangeetha Venugopal, Abhishek Maiti, Courtney D DiNardo, et al.
Cancer|January 30, 2023
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemiaKoji Sasaki, Farhad Ravandi, Tapan M Kadia, et al.
American Journal of Hematology|April 23, 2021
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burdenMusa Yilmaz, Naval Daver, Gautam Borthakur, et al.
American Journal of Hematology|November 6, 2025
Mixed-Phenotype Acute Leukemia With Mutated TP53: Genetic Landscape, Therapeutic Response, and OutcomesWei J Wang, Qiudan Shen, Mehrnoosh Tashakori, et al.
American Journal of Hematology|April 13, 2024
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implicationsTareq Abuasab, Gautam Borthakur, Rashmi Kanagal-Shamanna, et al.
American Journal of Hematology|November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionElias Jabbour, Johannes Düll, Musa Yilmaz, et al.
Cancer|March 7, 2023
Association between bariatric surgery and outcomes in chronic myeloid leukemiaFadi G Haddad, Hagop M Kantarjian, Aram Bidikian, et al.
American Journal of Hematology|March 31, 2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitorsFadi G Haddad, Koji Sasaki, Ghayas C Issa, et al.
American Journal of Hematology|March 10, 2022
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomabNicholas J Short, Walid Macaron, Marina Konopleva, et al.
Leukemia & Lymphoma|August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 yearsCatherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.
Pageof 35

Showing results (161-170 of 346) with videos related to

Sort By:
Pageof 35
American Journal of Hematology|February 13, 2021
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemiaSangeetha Venugopal, Abhishek Maiti, Courtney D DiNardo, et al.
Cancer|January 30, 2023
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemiaKoji Sasaki, Farhad Ravandi, Tapan M Kadia, et al.
American Journal of Hematology|April 23, 2021
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burdenMusa Yilmaz, Naval Daver, Gautam Borthakur, et al.
American Journal of Hematology|November 6, 2025
Mixed-Phenotype Acute Leukemia With Mutated TP53: Genetic Landscape, Therapeutic Response, and OutcomesWei J Wang, Qiudan Shen, Mehrnoosh Tashakori, et al.
American Journal of Hematology|April 13, 2024
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implicationsTareq Abuasab, Gautam Borthakur, Rashmi Kanagal-Shamanna, et al.
American Journal of Hematology|November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionElias Jabbour, Johannes Düll, Musa Yilmaz, et al.
Cancer|March 7, 2023
Association between bariatric surgery and outcomes in chronic myeloid leukemiaFadi G Haddad, Hagop M Kantarjian, Aram Bidikian, et al.
American Journal of Hematology|March 31, 2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitorsFadi G Haddad, Koji Sasaki, Ghayas C Issa, et al.
American Journal of Hematology|March 10, 2022
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomabNicholas J Short, Walid Macaron, Marina Konopleva, et al.
Leukemia & Lymphoma|August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 yearsCatherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.
Pageof 35